Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent

被引:5
|
作者
van Hoogstraten, Lisa M. C. [1 ,2 ]
Witjes, J. Alfred [3 ]
Meijer, Richard P. [4 ]
Ripping, Theodora M. [1 ]
Kiemeney, Lambertus A. [2 ,3 ]
Aben, Katja K. H. [1 ,2 ]
机构
[1] Netherlands Comprehens Canc Org, POB 1281, NL-6501 BG Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
关键词
muscle-invasive bladder cancer (MIBC); patient and tumour characteristics; survival; treatment; urothelial bladder carcinoma; variation in healthcare; #BladderCancer; #blcsm; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; MODALITY THERAPY; PRESERVATION; CHEMOTHERAPY; PATTERNS; SCORE;
D O I
10.1111/bju.15697
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs >= 75 years). Results One-third of patients aged >= 75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged >= 75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. Conclusion On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
引用
收藏
页码:764 / 775
页数:12
相关论文
共 50 条
  • [21] Natural history and health care burden of non-curative treatment for muscle-invasive bladder cancer
    Herzberg, Haim
    Ventura, Yossi
    Lifshitz, Karin
    Savin, Ziv
    Golan, Shay
    Baniel, Jack
    Yossepowitch, Ofer
    Mano, Roy
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (08) : 246.e7 - 246.e13
  • [22] Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
    Stenzl, Arnulf
    Cowan, Nigel C.
    De Santis, Maria
    Kuczyk, Markus A.
    Merseburger, Axel S.
    Jose Ribal, Maria
    Sherif, Amir
    Witjes, J. Alfred
    EUROPEAN UROLOGY, 2011, 59 (06) : 1009 - 1018
  • [23] Treatment of Muscle-Invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
    Stenzl, A.
    Cowan, N. C.
    De Santis, M.
    Kuczyk, M. A.
    Merseburger, A. S.
    Ribal, M. J.
    Sherif, A.
    Witjes, J. A.
    ACTAS UROLOGICAS ESPANOLAS, 2012, 36 (08): : 449 - 460
  • [24] Optimizing treatment for non muscle-invasive bladder cancer with an app
    Beardo, P.
    Pinto, R.
    Ayerra, H.
    Aguera, J.
    Armijos, S.
    Alvarez-Ossorio, J. L.
    ACTAS UROLOGICAS ESPANOLAS, 2022, 46 (04): : 230 - 237
  • [25] Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy
    Tappero, Stefano
    Garcia, Cristina Cano
    Incesu, Reha-Baris
    Piccinelli, Mattia Luca
    Barletta, Francesco
    Morra, Simone
    Scheipner, Lukas
    Tian, Zhe
    Saad, Fred
    Shariat, Shahrokh F.
    Borghesi, Marco
    Terrone, Carlo
    Karakiewicz, Pierre I.
    SURGICAL ONCOLOGY-OXFORD, 2023, 48
  • [26] TREATMENT OF NON-METASTATIC MUSCLE-INVASIVE BLADDER CANCER: AUA/ASCO/ASTRO/SUO GUIDELINE (vol 198, pg 552, 2017)
    Bochner, Bernard H.
    Rosenberg, Jonathan E.
    JOURNAL OF UROLOGY, 2017, 198 (05): : 1175 - 1175
  • [27] SURVIVAL ANALYSIS OF PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER NOT SUITABLE FOR TREATMENT WITH A CURATIVE INTENT
    Guerrero Ramos, Felix
    Perez Cadavid, Santiago
    Tejido Sanchez, Angel
    Garcia Rojo, Esther
    Gonzaiez Padilla, Daniel Antonio
    Sopena Sutil, Raquel
    Villacampa Auba, Felipe
    Duarte Ojeda, Jose Manuel
    de la Rosa Kehrmann, Federico
    Passas Martinez, Juan
    JOURNAL OF UROLOGY, 2017, 197 (04): : E728 - E728
  • [28] Management of patients with muscle-invasive and metastatic bladder cancer
    Henry, N. Lynn
    Macvicar, Gary
    Hussain, Maha
    ONCOLOGY-NEW YORK, 2005, 19 (10): : 1333 - 1342
  • [29] Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment
    Moller, Christina Tanem
    Fossa, Sophie D.
    Tafjord, Gunnar
    Babigumira, Ronnie
    Berge, Viktor
    Andreassen, Bettina Kulle
    SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (03) : 214 - 220
  • [30] A RETROSPECTIVE REVIEW OF RADIATION THERAPY IN NON-METASTATIC MUSCLE-INVASIVE BLADDER CANCER AT A TERTIARY CARE UNIVERSITY HOSPITAL IN PAKISTAN
    Hina, Mariam
    Ali, Nasir
    Abbasi, Ahmed Nadeem
    Khan, Agha Muhammad Hammad
    Lakhani, Sohail
    Mansha, Muhammad Atif
    Tariq, Maria
    Abrar, Sehrish
    Hafiz, Asim
    Qureshi, Bilal Mazhar
    RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S69 - S69